Form 4: Enliven Therapeutics CFO Benjamin Hohl Reports Stock Option Exercise and Sale

Benjamin Hohl, CFO of Enliven Therapeutics, executed a transaction involving the exercise of stock options and subsequent sale of common stock on October 1, 2024, according to a Form 4 filing with the SEC.

Summary

• On October 1, 2024, Benjamin Hohl, the Chief Financial Officer of Enliven Therapeutics, exercised stock options to acquire 521 shares of common stock at a price of $2.48 per share.
• Simultaneously, Hohl sold 521 shares of common stock at a weighted average price of $27.5372, with individual sales ranging from $27.52 to $27.54.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on June 26, 2023.
• Following the reported transactions, Hohl directly owns 192,358 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's perspective on the company's stock.

Stakeholder Impact

• Shareholders may be interested in the CFO's transactions as an indicator of management's confidence in the company.

Key Dates